| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K03536150 | CTRPv2 | pan-cancer | AAC | 0.073 | 0.04 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | -0.11 | 0.05 |
| mRNA | PHA-665752 | CCLE | pan-cancer | AAC | -0.092 | 0.05 |
| mRNA | NSC23766 | CTRPv2 | pan-cancer | AAC | 0.068 | 0.05 |
| mRNA | KU-55933 | CTRPv2 | pan-cancer | AAC | 0.069 | 0.05 |
| mRNA | BRD-K30748066 | CTRPv2 | pan-cancer | AAC | 0.22 | 0.05 |
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | -0.062 | 0.05 |
| mRNA | WH-4-023 | GDSC1000 | pan-cancer | AAC | -0.096 | 0.05 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.061 | 0.05 |
| mRNA | LFM-A13 | GDSC1000 | pan-cancer | AAC | -0.066 | 0.05 |